Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

Background Pain is a core domain of psoriatic arthritis (PsA). This post hoc analysis evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib.Methods Data from two trials (NCT01877668; NCT01882439) in patients receiving...

Full description

Bibliographic Details
Main Authors:	Roy Fleischmann, Peter C Taylor, Kurt de Vlam, Joseph C Cappelleri, Alexis Ogdie, Lara Fallon, John Woolcott, Valderilio Azevedo, Andrew G Bushmakin
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-08-01
Series:	RMD Open
Online Access:	https://rmdopen.bmj.com/content/7/2/e001609.full

Similar Items

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
by: Kurt de Vlam, et al.
Published: (2020-05-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
by: Laura C. Coates, et al.
Published: (2021-03-01)

Itch as Major Mediator of Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
by: Peter C. Taylor, et al.
Published: (2021-09-01)

Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies
by: Christopher T. Ritchlin, et al.
Published: (2020-10-01)

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
by: Daniela Graham, et al.
Published: (2021-04-01)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
by: Peter Nash, et al.
Published: (2018-11-01)

Obesity and Psoriatic Arthritis: A Narrative Review
by: Anand Kumthekar, et al.
Published: (2020-06-01)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
by: Ly K, et al.
Published: (2019-08-01)

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE
by: E. Yu. Loginova, et al.
Published: (2020-06-01)

Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis
by: T. V. Korotaeva, et al.
Published: (2019-05-01)

Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients
by: E. E. Gubar, et al.
Published: (2021-05-01)

Tofacitinib in baseline treatment of rheumatoid arthritis: own clinical experience
by: A. R. Babaeva, et al.
Published: (2016-12-01)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
by: Dafna D. Gladman, MD, et al.
Published: (2020-01-01)

Probiotic Use and Psoriatic Arthritis Disease Activity
by: Madison Grinnell, et al.
Published: (2020-06-01)

Psoriatic arthritis and the association with cardiometabolic disease: a narrative review
by: Paras Karmacharya, et al.
Published: (2021-03-01)

Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2021-06-01)

Measurement of pain and pain threshold in patients with arthritis
by: Huskisson, E. C.
Published: (1974)

The Role of Galanin in the Median Neuropathic Pain
by: Hsin-Fang Li, et al.
Published: (2012)

Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
by: Tanja Todberg, et al.
Published: (2020-08-01)

Classification and Outcome Measures for Psoriatic Arthritis
by: Ying Ying Leung, et al.
Published: (2018-09-01)

Longitudinal analysis of the patient pathways to diagnosis of psoriatic arthritis
by: Alexis Ogdie, et al.
Published: (2021-10-01)

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
by: Peter Nash, et al.
Published: (2020-06-01)

Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib
by: Maria Sole Chimenti, et al.
Published: (2021-02-01)

Evaluating Inflammatory Versus Mechanical Back Pain in Individuals with Psoriatic Arthritis: A Review of the Literature
by: Linda L. Grinnell-Merrick, et al.
Published: (2020-09-01)

Psychometric properties of the painDETECT questionnaire in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Rasch analysis and test-retest reliability
by: Signe Rifbjerg-Madsen, et al.
Published: (2017-05-01)

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years
by: Janet E. Pope, et al.
Published: (2019-04-01)

Relationships between changes in pain severity and other patient-reported outcomes: an analysis in patients with posttraumatic peripheral neuropathic pain
by: Zlateva Gergana, et al.
Published: (2011-03-01)

Measurement properties of painDETECT by average pain severity
by: Cappelleri JC, et al.
Published: (2014-11-01)

The Role of Nitric Oxide in the Median Nerve Neuropathic Pain
by: Hsin-ying Wang, et al.
Published: (2013)

Pain and microcrystalline arthritis
by: R. Ramonda, et al.
Published: (2014-06-01)

Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/ Spondyloarthritis Registry
by: Blachley, T., et al.
Published: (2022)

Characterizing individual painDETECT symptoms by average pain severity
by: Sadosky A, et al.
Published: (2016-07-01)

Characterizing neuropathic pain profiles: enriching interpretation of painDETECT
by: Cappelleri JC, et al.
Published: (2016-07-01)

In Patients with Early Peripheral Psoriatic Arthritis Baseline C-Reactive Protein, Pain and Ultrasound-Detected Synovitis Predict Subsequent Treatment with ts/bDMARDs. A Retrospective Analysis
by: Garifallia Sakellariou, et al.
Published: (2021-06-01)

Features of Pain Syndrome and Psychoemotional State in Patients with Psoriatic Arthritis Depending on Whether They Have Symptoms of Autonomic Dysfunction
by: I.I. Blaginina
Published: (2014-02-01)

The efficacy of pregabalin for the treatment of neuropathic pain in Japanese subjects with moderate or severe baseline pain
by: Parsons B, et al.
Published: (2019-03-01)

Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study
by: Muhammad Haroon, et al.
Published: (2018-04-01)

Widespread pain in axial spondyloarthritis: clinical importance and gender differences
by: Thijs Willem Swinnen, et al.
Published: (2018-07-01)

A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements
by: A. E. Karateev, et al.
Published: (2020-05-01)

Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis
by: David Cella, et al.
Published: (2019-05-01)